Edit |   |
---|---|
Antigenic Specificity | ErbB-3 (Her-3), Human |
Clone | REA508 |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG1 |
Format | Vio Bright FITC conjugate |
Size | 100 tests in 1 mL |
Concentration | 1:11 |
Applications | Flow cytometry |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | ErbB-3 (Her-3) Antibody, anti-human, Vio® Bright FITC, REAfinity™. Clone REA508 recognizes the human ErbB-3 antigen, a single-pass type I membrane protein, which is also known as tyrosine kinase-type cell surface receptor HER3. ErbB-3 is a receptor tyrosine kinase and a member of the epidermal growth factor receptor family (EGFR). It is unique among the ErbB family members in that it is has been shown to have weak or no tyrosine kinase activity. After dimerization with other members of the EGFR family several signal transduction cascades can be activated, including phosphoinosite 3'-kinase (PI3-K)/Akt and extracellular signal-regulated kinase (ERK1/2). ErbB-3 is widely expressed in normal tissues including cells of the gastrointestinal, reproductive, respiratory and urinary tracts, as well as the skin, endocrine, and nervous system. It is expressed at elevated levels in a range of human malignancies. | Additional information: Clone REA508 displays negligible binding to Fc receptors. |
Immunogen | n/a |
Other Names | ErbB3, HER3, LCCS2, MDA-BF-1, c-ErbB-3, erbB3-S, ErbB3 |
Gene, Accession # | Gene ID: 2065 |
Catalog # | 130-107-903 |
Price | $395 |
Order / More Info | ErbB-3 (Her-3), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Kraus, M. H. et al. (1989) Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. U.S.A. 86 (23): 9193-9197. | Citri, A. et al. (2003) The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp. Cell Res. 284 (1): 54-65. | Ghasemi, R. et al. (2014) Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. Oncogenesis 3: 117. |